AN2 THERAPEUTICS INC (ANTX)
Health Care · biotechnology · NASDAQ
AN2 Therapeutics is a clinical-stage biopharmaceutical company leveraging a proprietary boron chemistry platform to develop novel small-molecule drugs for infectious diseases and cancer.
What AN2 THERAPEUTICS INC does
AN2 Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics using its proprietary boron chemistry platform. Its development pipeline primarily targets infectious diseases, hematologic cancers, and solid tumors. The company's lead product candidate, epetraborole, is being evaluated for polycythemia vera and Mycobacterium abscessus complex lung disease, while AN2-502998 is in development for chronic Chagas disease.
Recent developments
The company announced plans to expand its Phase 2 study of epetraborole in polycythemia vera to include U.S. and Australian sites, with an IND filing expected in Q3 2026. Additionally, the company is advancing a second development candidate for solid tumors, expected by the end of 2026.
From AN2 THERAPEUTICS INC's filing of 2026-08-11.
Themes: boron-based therapeutics, hematologic oncology, infectious disease drug development, solid tumor immuno-oncology
Fundamentals
- Price$3.56 as of 2026-10-20 close
- Market cap$134M as of 2026-08-06 (share count; price 2026-10-20)
- 1-year return+191.8% 2025-10-20 close $1.22 → 2026-10-20 close $3.56
- P/En/a negative earnings
- ROE-66.3% FY2025, SEC XBRL
- ROICn/a No figure: its 10-K tags no pre-tax income, so no tax rate can be taken.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Beta0.65 as of 2026-09-03
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How ANTX compares in its sector
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-03
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Operating income | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | -$9M | -$8M | -$0.18 | -$7M† |
| Q1 FY2026 2026-03-31 | -$11M | -$10M | -$0.29 | -$12M |
| Q4 FY2025 2025-12-31 | -$9M† | -$9M† | -$0.28† | -$5M† |
| Q3 FY2025 2025-09-30 | -$10M | -$9M | -$0.31 | -$6M† |
| Q2 FY2025 2025-06-30 | -$7M | -$6M | -$0.21 | -$8M† |
| Q1 FY2025 2025-03-31 | -$12M | -$11M | -$0.35 | -$11M |
| Q4 FY2024 2024-12-31 | -$9M† | -$8M† | -$0.25† | -$5M† |
| Q3 FY2024 2024-09-30 | -$14M | -$13M | -$0.43 | -$12M† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$44M
- Short-term investments$34M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How AN2 THERAPEUTICS INC looks technically
AN2 THERAPEUTICS INC (ANTX) is trading 9.0% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 155 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 29, in oversold territory (below 30). MACD, a trend-momentum gauge, turned bearish about 9 trading days ago (its momentum flipped negative). It made a new 20-day low about 2 trading days ago. It is 50.5% below its highest point of the past year. Trading volume is unusually light — only about 43% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 9.0% below its 200-day average, the long-term trend line — a long-term downtrend | -9.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $5.21 | $5.21 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.91 | $3.91 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 47 calendar days ago — the swings before that are what the structure reading is measured on | 47 sessions |
| Wave structure | its recent swings can be read as a completed five-part upward sequence — the pattern Elliott-wave chartists call an impulse — which on that reading would now be due a pullback rather than more of the same; the labelling fails if price closes above 6.2. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible five-wave upward sequence, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 155 trading days ago — a "golden cross", a bullish long-term signal | 155 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with sellers in control | 31.1 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 29, in oversold territory (below 30) | 28.6 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($3.22 to $5.99) — its "stochastic" reading is 12 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 12.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 9 trading days ago (its momentum flipped negative) | 9 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $7.19 | $7.19 |
|---|---|---|
| From the 52-week high | it is 50.5% below its 52-week high (its highest price of the past year) | -50.5% |
| Above the 52-week low | it is 256.0% above its 52-week low (its lowest price of the past year) | +256.0% |
| Below the 52-week high | it is 50.5% below its highest point of the past year | 50.5% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day low about 2 trading days ago | 2 sessions |
| All-time high | its highest closing price on record is $22.48 (set on 2022-08-15) | $22.48 |
| Given back of the 52-week move | over the past year its closes ranged ($1.03 to $6.28), and it has given back around half of its rise from last year’s low — 52% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $2.87 to $3.04. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 51.8% |
| From the all-time high | it is 84.2% below its all-time high | -84.2% |
| Nearest price level | it is trading 44.2% below a resistance level at $5.13 — a price it turned at twice since 2026-04-27, most recently on 2026-05-05. Since 2024-10-21 it has 10 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +44.2% |
| All-time low | its lowest closing price on record is $0.87 (set on 2024-08-09) | $0.87 |
| Above the all-time low | it is 309.2% above its all-time low | +309.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 96% of the past ~6 months) | 96th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.3663 between its high and its low — about 10.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.3663 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.01 and $6.12 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.01 – $4.57 – $6.12 |
| Typical daily range (% of price) | its price moves about 10.3% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 10.3% |
| Stretch from the 200-day average | it is trading 1.0 daily range below its 200-day average price (9.0% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.0 daily range below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 43% of its 30-day average | 0.43× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
3
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-20 0.3% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.3% |
|---|---|---|
| Open gap | it gapped 3.9% below the previous close 10 sessions ago and has not traded back through the level it left behind at 5.61 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -3.9% |
| Gap filled | a 3.0% gap down opened on 2026-09-10 has been "filled" 28 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 28 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 30.5 percentage points (the stock lost 29.5% while the market gained 1.0%) | -30.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 29.5 percentage points (the stock lost 25.8% while the market gained 3.6%) | -29.5% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 10.2 percentage points (the stock lost 1.7% while the market gained 8.5%) | -10.2% |
| vs market, 12 months | over the past 12 months this stock beat the market by 177.2 percentage points (the stock gained 191.8% while the market gained 14.6%) | +177.2% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, its RSI momentum gauge is oversold (a beaten-down reading), near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 37% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 10.6% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -36.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 24% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $4.71 — a volume-weighted average of daily closes over 198 sessions, not a true tick-by-tick VWAP. | -24.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 30% below the average price paid since it last reported on 2026-08-11 (its 10-Q), so the typical buyer over that stretch is under water. That average is $5.12 — a volume-weighted average of daily closes over 50 sessions, not a true tick-by-tick VWAP. | -30.4% |
Price levels it has turned at before
ANTX last closed at $3.56 on 2026-10-20. Since 2024-10-21 it has turned at 10 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $5.13 | Resistance | 44.2% above the last close | turned there twice · 2026-04-27 to 2026-05-05 |
| $5.24 | Resistance | 47.1% above the last close | turned there twice · 2026-05-22 to 2026-07-20 |
| $1.35 | Support | 61.9% below the last close | turned there twice · 2025-10-27 to 2026-01-08 |
| $1.29 | Support | 63.8% below the last close | turned there twice · 2025-05-07 to 2025-09-03 |
| $1.23 | Support | 65.5% below the last close | turned there four times · 2024-12-19 to 2025-12-18 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $6.20.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 4 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 28 trading days, since 2026-09-11.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Oversold (14-day RSI below 30) · Pulled back from the 12-month high · Broke down to a new 20-day low · lagging the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$9.00 range $9.00 – $9.00
Analyst estimates, as of 2026-10-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ANTX
- Consensus EPS estimate-$0.2 next reporting period, as of 2026-10-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical development is high-risk, uncertain, and costly, with no guarantee that any product candidate will receive regulatory approval or be commercially viable.","The company is in the early stages of development and has a history of losses, with significant future financing needs to fund planned clinical trials.","Reliance on proprietary boron chemistry platform; failure to demonstrate success with lead programs could jeopardize the company's financial condition and growth prospects."]
What changed in the latest 10-Q
AI-assisted comparison of ANTX's 10-Q filed 2026-08-11 against the prior one filed 2026-05-11.
Risk Factors
- Added:
- Newer filing includes quarterly results and analysis for the three months ended June 30, 2026 and June 30, 2025.
- Newer filing includes quarterly results and analysis for the six months ended June 30, 2026 and June 30, 2025.
- Newer filing includes an 'Other expense' line item in the results of operations tables for the three and six months ended June 30, 2026.
- Newer filing includes a discussion of a decrease in research and development personnel-related expenses attributed to decreased stock-based compensation.
- Newer filing includes a discussion of a decrease in general and administrative expenses attributed to decreases in professional and outside services expenses and personnel-related expenses.
- Newer filing includes a statement that during the three months ended June 30, 2026 and 2025, reimbursement of $0.4 million and $3.7 million, respectively, of operating expenses was recognized related to funding arrangements.
- Removed:
- Older filing includes quarterly results and analysis for the three months ended March 31, 2026 and March 31, 2025.
- Older filing includes a 'Liquidity and Capital Resources' section with sources of liquidity, cash, and financing history as of March 31, 2026.
- Older filing includes an 'Interest income' line item without net adjustment in the results of operations table.
- Older filing includes a discussion of decreases in CMC expenses and license fees for the three months ended March 31, 2026.
- Older filing includes a statement that during the three months ended March 31, 2026 and 2025, reimbursement of $0.7 million and $0.4 million, respectively, of operating expenses was recognized related to funding arrangements.
- Reworded:
- Newer filing changed the 'Interest income' line item to 'Interest income, net'.
- Newer filing's results of operations comparison periods changed from the three months ended March 31 to the three and six months ended June 30.
- Notes:
- The newer filing text appears to be truncated mid-sentence in the six-month research and development expenses discussion.
- The older filing provided is not a 'Risk Factors' section but rather an MD&A section, matching the newer filing content; the section label in metadata may be inaccurate.
- The newer filing includes substantial financial data not present in the older filing because the reporting periods differ.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
1 open-market purchase and 9 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 90 days · read to 2026-10-161 buy ($11602) · 9 sells ($318205) — 1 buying, 2 selling insiders
- Last 180 days · read to 2026-10-161 buy ($11602) · 11 sells ($344181) — 1 buying, 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-09. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ANTX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding ANTX as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 4,010,851
- Reported value $19,412,518
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about ANTX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
ANTX had 2,491,971 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
ANTX had 6.60% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.54 days to cover at the same settlement.
- Reported short interest (shares) 2,491,971
- Short interest (% of shares outstanding) 6.60%
- Prior settlement (shares) 2,397,307
- Reported change 3.95%
- Days to cover (reported) 9.54
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Incyte (INCY)
- Blueprint Medicines (BPMC)
- Insmed (INSM)
- Atea Pharmaceuticals (AVIR)
- Keros Therapeutics (KROS)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ANTX vs…
Frequently asked questions
What does AN2 THERAPEUTICS INC (ANTX) do?
AN2 Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics using its proprietary boron chemistry platform. Its development pipeline primarily targets infectious diseases, hematologic cancers, and solid tumors. The company's lead product candidate, epetraborole, is being evaluated for polycythemia vera and Mycobacterium abscessus complex lung disease, while AN2-502998 is in development for chronic Chagas disease.
What sector is AN2 THERAPEUTICS INC (ANTX) in?
AN2 THERAPEUTICS INC (ANTX) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are AN2 THERAPEUTICS INC's (ANTX) competitors?
Notable peers of AN2 THERAPEUTICS INC (ANTX) include Incyte, Blueprint Medicines, Insmed, Atea Pharmaceuticals and Keros Therapeutics. This peer set is informational only — not financial advice.
Is AN2 THERAPEUTICS INC (ANTX) overbought or oversold right now?
AN2 THERAPEUTICS INC (ANTX) is currently in oversold territory (its 14-day RSI is 29, below 30) (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ANTX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.